Romoli M, Jelcic I, Bernard‐Valnet R, et al. - Researchers systematically examined available evidence for reports of neurological signs and symptoms in patients with COVID‐19 to distinguish cases with severe acute respiratory syndrome coronavirus (SARS‐CoV)‐2 infection or immune‐mediated reaction in the nervous system. Researchers followed PRISMA guidelines and carried out to search MEDLINE, EMBASE, Google Scholar, MedRxiv, and ChinaXiv databases for articles on COVID‐19 and nervous system involvement that were published between 1 January and 24 April 2020. They extracted data on design, sample size, neurological assessment, and related work‐up. With the Newcastle–Ottawa scale, biases were assessed. Twenty-seven publications on potential neuroinvasive or parainfectious neurological complications of COVID‐19 were examined. In this systematic review, it was failed to develop comprehensive insights into nervous system manifestations of COVID‐19 beyond immune‐mediated complications in the aftermath of respiratory symptoms. The researchers thus serve guidance for more careful clinical, diagnostic, and epidemiological research to define the manifestations and burden of neurological disease caused by SARS‐CoV‐2 on behalf of the Infectious Disease Panel of the European Academy of Neurology.